Last reviewed · How we verify
NCT03847714: PIDE
Probiotics in Dementia
NA trial testing Omni-Biotic Stress Repair in Dementia; Alzheimer, Mixed Type (Etiology) in 17 participants. Completed in 31 December 2024.
31 December 2024
Quick facts
| Lead sponsor | Medical University of Graz |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 17 |
| Start date | 15 June 2019 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Omni-Biotic Stress Repair
- placebo
Conditions studied
- Dementia; Alzheimer, Mixed Type (Etiology) — all drugs for Dementia; Alzheimer, Mixed Type (Etiology) →
Sponsor
Medical University of Graz
Who can join
18 and older, any sex, with Dementia; Alzheimer, Mixed Type (Etiology). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dementia is associated with changes in gut microbiome composition, gut barrier dysfunction, intestinal inflammation and systemic inflammation. Probiotics are a possibility to modulate the gut-brain axis. In this study the effect of probiotics on the gut microbiome and, gut barrier function, inflammation and cognitive dysfunction will be studied.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS.
Liu L, Huh JR, Shah K. · · 2022 · cited 199× · PMID 35255456 · DOI 10.1016/j.ebiom.2022.103908 -
Unraveling brain aging through the lens of oral microbiota.
Hu Q, Wang S, Zhang W, Qu J, et al · · 2025 · cited 5× · PMID 38993126 · DOI 10.4103/nrr.nrr-d-23-01761 -
The Gut-Brain-Immune Axis in Glioma: Emerging Mechanisms and Therapeutic Opportunities.
Feng R, Yang Z, Zhou Y, Zhao H. · · 2026 · PMID 41677988 · DOI 10.1007/s10571-026-01680-3
Verify or expand the search:
- PubMed search for NCT03847714
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Medical University of Graz trials
Trials by the same sponsor.
- NCT07498244 — Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients · recruiting
- NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
- NCT07297615 — 3D Liver Volumetry · NA · not yet recruiting
- NCT07588282 — The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intention · NA · recruiting
- NCT07376096 — Liquid Biopsy in Germ Cell Tumors · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03847714 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Graz
- Last refreshed: 12 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03847714.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing